A novel triaptosis-related prognostic signature to assess the clinical value in HER2-low breast cancer: evidence from clinical cohorts and experimental validation - PubMed
4 days ago
- #PYDC1
- #prognostic signature
- #HER2-low breast cancer
- A novel triaptosis-related prognostic signature was developed for HER2-low breast cancer (BC).
- The signature includes genes LRP6, EMB, PYDC1, CEACAM6, and AGR3, showing excellent predictive efficacy in multiple cohorts.
- PYDC1 was identified as a suppressor of PI3K/AKT signaling, inhibiting proliferation and migration in HER2-low BC cells.
- The study highlights the clinical relevance of triaptosis-related genes (TRGs) as biomarkers, not direct evidence of triaptotic cell death.
- The research was validated using clinical cohorts and experimental assays, with no conflicts of interest declared.